Abstract
Nineteen evaluable patients with advanced endometrial cancer refractory to one prior chemotherapeutic regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicity was grade 2 or greater leukopenia in 45% of patients. Fludarabine phosphate at this dose and schedule does not appear to be an active agent for patients with refractory endometrial cancer.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Antimetabolites, Antineoplastic / adverse effects
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Drug Administration Schedule
-
Drug Evaluation
-
Female
-
Hematologic Diseases / chemically induced
-
Humans
-
Middle Aged
-
Uterine Neoplasms / drug therapy*
-
Vidarabine Phosphate / adverse effects
-
Vidarabine Phosphate / analogs & derivatives*
-
Vidarabine Phosphate / therapeutic use
Substances
-
Antimetabolites, Antineoplastic
-
Vidarabine Phosphate
-
fludarabine phosphate